Artiva COO Jennifer Bush sells 8,391 shares

Artiva Biotherapeutics officer Jennifer Bush executed an automatic sell-to-cover stock sale tied to RSU vesting, retaining over three hundred thousand shares afterward.

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) reported that officer Jennifer Bush, the company's COO, CLO and Compliance Officer, sold 8,391 shares of common stock on September 3, 2026. The company states these sales were automatic sell-to-cover transactions for tax withholding on vesting restricted stock units, not discretionary trades, leaving her with 329,529 shares held directly.

Insider Trade Summary

Net Seller: 8,391 shares

Net Sell 1 txn

Insider Bush Jennifer

Role COO, CLO, Compliance Officer

Sold 8,391 shs ($94K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	8,391	$11.1555	$94K

Holdings After Transaction: Common Stock — 329,529 shares (Direct)

Footnotes (2)

1. F1. The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
2. F2. The weighted average sale price for the transaction reported was $11.1555, and the range of prices were between $11.0350 and $11.1556. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Shares sold: 8,391 shares Weighted average sale price: $11.1555 per share Post-transaction holdings: 329,529 shares +2 more

5 metrics

Shares sold 8,391 shares Common stock sold by Jennifer Bush on September 3, 2026

Weighted average sale price $11.1555 per share Average price for the reported sale transaction

Post-transaction holdings 329,529 shares Common stock held directly by Jennifer Bush after the sale

Price range $11.0350–$11.1556 per share Range of prices for shares sold in the transaction

Net shares sold 8,391 shares Net sell activity reported in the Form 4

Key Terms

sell-to-cover, restricted stock units, weighted average sale price

3 terms

sell-to-cover financial

"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax"

Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.

restricted stock units financial

"cover tax withholding obligations in connection with the vesting and release of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $11.1555"

FAQ

What insider transaction did ARTV report for Jennifer Bush on this Form 4?

Artiva Biotherapeutics reported that officer Jennifer Bush sold 8,391 shares of common stock on September 3, 2026. The company describes the transaction as an automatic sell-to-cover sale related to tax withholding on vesting restricted stock units.

Was the ARTV insider sale by Jennifer Bush a discretionary trade?

No. The company states it has a "sell-to-cover" policy for tax withholding, and the sales were automatic and not at the discretion of Jennifer Bush. The shares were sold to satisfy tax withholding obligations from the vesting and release of restricted stock units.

How many ARTV shares does Jennifer Bush hold after the reported sale?

After the transaction, Jennifer Bush is reported to hold 329,529 shares of Artiva Biotherapeutics common stock directly. This figure reflects her position following the automatic sale of 8,391 shares for tax withholding purposes.

At what price were the 8,391 ARTV shares sold by Jennifer Bush?

The filing reports a weighted average sale price of $11.1555 per share for the transaction. It notes that individual sale prices ranged between $11.0350 and $11.1556, and that detailed price breakdowns are available upon request.

Is the ARTV insider sale associated with a Rule 10b5-1 trading plan?

No Rule 10b5-1 trading plan is reported. Instead, the company explains the sale resulted from a corporate sell-to-cover policy for tax withholding tied to the vesting of restricted stock units, and that the sale was automatic.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:04 PM Accepted by SEC EDGAR 09/04/2026 - 04:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bush Jennifer

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO, CLO, Compliance Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2026		S		8,391(1)	D	$11.1555(2)	329,529	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The weighted average sale price for the transaction reported was $11.1555, and the range of prices were between $11.0350 and $11.1556. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Andrew Cronauer, Attorney-in-Fact	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)